公司资料
Aptose Biosciences, Inc. 股价、新闻与催化剂
- 股票代码:
- APTO
- 交易所:
- NASDAQ
- 行业:
- Biopharma
- 所在地:
- Canada and listed in the U
股价为何变动
Current closing-price context is not available for APTO.
公司概览
Precision Hematology Company
Aptose Biosciences develops small-molecule precision oncology therapies, with an initial focus on acute myeloid leukemia.
Tuspetinib Triplet
The TUSCANY study evaluates tuspetinib with venetoclax and azacitidine as a frontline regimen for newly diagnosed AML patients who are ineligible for intensive induction chemotherapy.
Mutation-Agnostic Strategy
The triplet is intended to provide activity across a genetically diverse AML population without adding overlapping toxicities to the standard venetoclax and azacitidine backbone.
未来催化剂
- Updated Phase 1/2 TUSCANY clinical data for the tuspetinib triplet are scheduled for an oral presentation at the June 2026 EHA Congress.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。